TABRECTA

novartis pharmaceuticals canada inc🇨🇦 Health Canada

Approval Id: 4369416c86cfca9b
Drug Approval Canada Name: TABRECTA
Product Name: TABRECTA
Status: Marketed
Status Date: 2022-09-16
Original Market Date: 2022-09-16
Din: 02527405
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 10:00.00
Atc Original: L01EX17 CAPMATINIB
Atc Name: l 01 ex 17
Aig Number: 0163681002
Company Name: novartis pharmaceuticals canada inc
Company Address: 100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1

CAPMATINIB (CAPMATINIB HYDROCHLORIDE)

200 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

4369416c86cfca9b

Type

Standard